secwatch.observer — SEC 8-K summary
======================================

Issuer:     GILEAD SCIENCES, INC. (GILD)
CIK:        0000882095
Form:       8-K/A
Filed at:   2024-12-13T23:59:59+00:00
Accession:  0001104659-24-128088
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gilead appoints Dietmar Berger as Chief Medical Officer effective Jan 2, 2025
-----------------------------------------------------------------------------

- Dietmar Berger, MD PhD, will become Chief Medical Officer and member of senior leadership team on January 2, 2025.
- Berger succeeds Merdad Parsey, MD PhD, who will stay as Senior Advisor through Q1 2025.
- Berger previously served as Chief Medical Officer and Global Head of Development at Sanofi.
- Berger will oversee Gilead's virology, oncology, inflammation portfolio and global Development/Medical Affairs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/882095/000110465924128088/0001104659-24-128088-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/882095/000110465924128088/tm2430889d1_8ka.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-128088

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer